Bioverativ (BIVV) Rating Reiterated by Argus

Bioverativ (NASDAQ:BIVV)‘s stock had its “hold” rating reiterated by stock analysts at Argus in a research report issued to clients and investors on Wednesday, MarketBeat reports.

A number of other equities analysts have also weighed in on BIVV. Morgan Stanley reaffirmed an “underweight” rating and issued a $47.00 target price (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 target price for the company in a research note on Thursday, October 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a research note on Monday, November 20th. Finally, Jefferies Group upped their target price on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research note on Thursday, January 18th. Thirteen equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $62.53.

Shares of Bioverativ (NASDAQ BIVV) traded down $0.37 during mid-day trading on Wednesday, hitting $103.03. 3,529,663 shares of the stock traded hands, compared to its average volume of 2,510,000. Bioverativ has a one year low of $41.88 and a one year high of $104.30. The firm has a market cap of $11,150.00 and a price-to-earnings ratio of 25.19.

Bioverativ (NASDAQ:BIVV) last announced its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. The firm had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm’s revenue was up 27.2% on a year-over-year basis. research analysts anticipate that Bioverativ will post 2.87 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. acquired a new position in shares of Bioverativ during the 4th quarter worth about $105,000. Advisors Asset Management Inc. acquired a new position in shares of Bioverativ during the 3rd quarter worth about $137,000. TCI Wealth Advisors Inc. acquired a new position in shares of Bioverativ during the 3rd quarter worth about $186,000. Ladenburg Thalmann Financial Services Inc. acquired a new position in shares of Bioverativ during the 3rd quarter worth about $190,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Bioverativ during the 3rd quarter worth about $194,000. Institutional investors own 96.04% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/28/bioverativ-bivv-rating-reiterated-by-argus.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Analyst Recommendations for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply